<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01939093</url>
  </required_header>
  <id_info>
    <org_study_id>NRCT-53069</org_study_id>
    <nct_id>NCT01939093</nct_id>
  </id_info>
  <brief_title>Therapeutic Effect of Quetiapine on Methamphetamine-Induced Psychosis</brief_title>
  <acronym>MAP</acronym>
  <official_title>Therapeutic Effect Between Quetiapine and Haloperidol on the Treatment of Methamphetamine - Induced Psychosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thanyarak Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Research Council of Thailand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of this study are to compare the antipsychotic and adverse events of quetiapine, an
      atypical antipsychotic drug, to haloperidol, a standard treatment for primary psychotic
      disorder, in individuals with MAP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eighty individuals with MAP will be randomly assigned into two treatment groups, i.e.
      treatment with quetiapine and haloperidol. The quetiapine group will receive quetiapine at
      least 100 mg per day and the haloperidol group will receive haloperidol at least 2 mg per day
      orally once a day for four weeks. The doses will be increased every 5 days until no psychotic
      symptom is observed from the Positive and Negative Syndrome Scale. Common antipsychotic
      adverse events will be checked and documented daily.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positive and Negative Syndrome Scale</measure>
    <time_frame>Every day in Week 1.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Positive and Negative Syndrome Scale</measure>
    <time_frame>Every two days in Week 2 and 3.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antipsychotic Adverse Event Form</measure>
    <time_frame>Every day for three weeks.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Methamphetamine-induced Psychosis</condition>
  <arm_group>
    <arm_group_label>Quetiapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quetiapine 100 mg per day is taken orally once a day for four weeks. The dose is increased every 5 days until no psychotic symptom is observed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Haloperidol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Haloperidol 2 mg per day is taken orally once a day for four weeks. The dose is increased every 5 days until no psychotic symptom is observed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diazepam</intervention_name>
    <description>If subjects had aggressive or violent symptoms and immediate symptom control was needed, 10 mg of diazepam (intravenous injection) every 4 hours is allowed for symptom control.</description>
    <arm_group_label>Quetiapine</arm_group_label>
    <arm_group_label>Haloperidol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin B1-6-12</intervention_name>
    <description>All subjects will be given the Institute's medication regimen, including vitamin B1-6-12 1 tablet three times a day after meals during the whole study period.</description>
    <arm_group_label>Quetiapine</arm_group_label>
    <arm_group_label>Haloperidol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stugeron</intervention_name>
    <description>All subjects will be given the Institute's medication regimen, including stugeron 1 tablet three times a day after meals during the whole study period.</description>
    <arm_group_label>Quetiapine</arm_group_label>
    <arm_group_label>Haloperidol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Having a psychotic episode with current use of methamphetamine

          -  Positive urine toxicology test for methamphetamine on the first day of hospitalization

        Exclusion Criteria:

          -  Using other illegal substances

          -  Having a history of primary psychotic disorders or using antipsychotic agents

          -  Having a chronic medical disease, e.g. essential hypertension, diabetes, epilepsy,
             stroke
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Viroj Verachai, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thanyarak Institute on Drug Abuse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thanyarak Institute on Drug Abuse</name>
      <address>
        <city>Pathumthani</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2013</study_first_submitted>
  <study_first_submitted_qc>September 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2013</study_first_posted>
  <last_update_submitted>September 5, 2013</last_update_submitted>
  <last_update_submitted_qc>September 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chulalongkorn University</investigator_affiliation>
    <investigator_full_name>Rasmon Kalayasiri</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Quetiapine</keyword>
  <keyword>Haloperidol</keyword>
  <keyword>Methamphetamine</keyword>
  <keyword>Psychosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Shared Paranoid Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Thiamine</mesh_term>
    <mesh_term>Quetiapine Fumarate</mesh_term>
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Haloperidol decanoate</mesh_term>
    <mesh_term>Diazepam</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
    <mesh_term>Methamphetamine</mesh_term>
    <mesh_term>Cinnarizine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

